CC's goal in conducting this study is to provide an overview of the current and potential aspects of the global market for liver diseases treatments market. The report determines the market size and market leaders, provides a market overview, and examines factors affecting the markets for drugs used to treat liver diseases. The markets have been defined by disease type and by drug type.

1. LIver Disease Treatments: The Global Market
ReportsnReports.com adds BCC Research Market Research Report “LIver Disease
Treatments: The Global Market’’ to its store.
STUDY OBJECTIVES
BCC’s goal in conducting this study is to provide an overview of the current and potential
aspects of the global market for liver diseases treatments market. The report determines
the market size and market leaders, provides a market overview, and examines factors
affecting the markets for drugs used to treat liver diseases. The markets have been defined
by disease type and by drug type.
The overview of types of liver diseases, their symptoms and their treatments is examined
along with sales figures over the five-year period from 2009 to 2014. The report also gives
the demand and use criteria of the drugs used to treat liver diseases, as well as an overview
of drug-induced liver diseases. Companies manufacturing and selling the drug products in
this category are profiled, and factors affecting markets for these products and how the
markets are likely to change are analyzed. Revenues have been broken down by the type of
diseases and by different regions.
Our key objective is to present a comprehensive analysis of the current market and the
future direction of the drugs used to treat liver diseases.
REASONS FOR DOING THIS STUDY
A large number of studies are currently ongoing regarding hepatitis and other liver diseases,
which influenced BCC’s desire to study this market.
This study looks at almost all of the types of products used to treat liver diseases, The
research and development of new products, and the changes in market behavior that justify
focusing on this segment. Finally, this study discusses the usage of these products.
INTENDED AUDIENCE
The study contributes to understanding market growth and decline in the market for liver
disease treatments, from the point of view of the manufacturer and user. This study will be
of interest largely to the chemical, pharmaceutical and biopharmaceutical industries, as well
as clinics and hospitals.
SCOPE OF THE STUDY
The scope of this study encompasses the market for liver disease treatments. BCC analyzes
each market and its leaders, the different types of liver diseases, the different types of drug
products to treat liver diseases, the regulatory environment, the regional market for liver
diseases and the drug products used to treat them, and market projections and market
share. Technological issues include latest trends and new developments.
METHODOLOGY
A combination of primary and secondary research methods were used in this study. A

2. comprehensive search of literature was conducted. The literature included technical
newsletters and journals as well as many other sources. The data were collected through
interviews and correspondence with various pharmaceutical/ biotechnical experts.
Projections were based on estimates such as the current number of end users, potential end
users, likely unit prices, rates of consumption, and market trends.
INFORMATION SOURCES
BCC surveyed many companies to obtain data for this study. Included were manufacturers
and the end users of the drugs used to treat liver diseases. We gathered industry data,
spoke with officials from this industry, and consulted newsletters, company literature,
product literature, and a host of technical articles, journals, indexes, and abstracts.
Exhaustive investigations of databases by key terminology were done. In addition, we
compiled data from current financial and trade information and government sources.
ABOUT THE AUTHOR
Shalini Shahani Dewan holds a Masters Degree in pharmaceutical chemistry. Among the
research topics she has covered are studies on compounds of potential pharmaceutical
interest from ibuprofen and 2-naphthyl acetic acid. Shahani was awarded a gold medal by
the Prime Minister of India for her work and has worked with top companies in India and in
the U.S. Some of her other reports with BCC are: Reagents of Chromatography;
Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs,
Implants and Devices; Imaging Reagents; Contract Manufacturing, Research and
Packaging; The Dynamic Media, Sera and Reagent Market in Biotechnology; Opportunities in
Chiral Technology; Behavioral and Emotional Disorders in Children and Adolescents;
Pharmaceutical Regulatory Industry,and many more.
Table Of Contents
Chapter- 1: INTRODUCTION – Complimentary
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR
RELATED REPORTS
BCC ONLINE SERVICES
DISCLAIMER
Chapter- 2: SUMMARY
Table 0 : GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014
Figure 0 : GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014
Chapter- 3: OVERVIEW
DEFINITIONS
THE LIVER
Chapter- 4: REGULATORY ISSUES

3. Table 2 : APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005–2008
Table 3 : NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER
DISEASES, 2005–2008
Figure 1 : NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER
DISEASES, 2005–2008
Table 4 : NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES,
2005–2008
Table 5 : RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005–2008
Chapter- 5: PREVALENCE
UNITED STATES
UNITED KINGDOM
REST OF THE WORLD
PREVALENCE OF A FEW LIVER DISEASES
Chapter- 6: CLASSIFICATION OF THERAPIES BY DISEASE
VIRUS-INDUCED LIVER DISEASE/HEPATITIS
LIVER TUMORS/ LIVER CANCER
CONGENITAL LIVER DEFECTS
AUTOIMMUNE LIVER DISORDERS
ALCOHOL-INDUCED LIVER DISEASE
CHRONIC LIVER DISEASE
NON-ALCOHOLIC FATTY LIVER
Chapter- 7: INDUSTRY STRUCTURE
HEPATITIS
LIVER TUMORS
AUTOIMMUNE DISEASES
ALCOHOL-INDUCED LIVER DISEASES
CHRONIC LIVER DISEASE
NON-ALCOHOLIC FATTY LIVER DISEASE
Chapter- 8: DEMAND AND USE
LIFE EXPECTANCY
LACK OF KNOWLEDGE
LACK OF TREATMENT OPTIONS
INCREASING NUMBER OF PATIENTS
RESEARCH AND DEVELOPMENT
INITIATIVES OF VARIOUS ORGANIZATIONS TO INCREASE AWARENESS
Chapter- 9: MARKET ANALYSIS
HEPATITIS
LIVER TUMORS
AUTOIMMUNE DISEASES
ALCOHOL-INDUCED LIVER DISEASE
CHRONIC LIVER DISEASES
NON-ALCOHOLIC FATTY LIVER DISEASE

4. Chapter- 10: DRUG-INDUCED LIVER DISEASE
DRUGS THAT CAN CAUSE LIVER DISEASE
Chapter- 11: NEW DEVELOPMENTS
CLINICAL TRIALS
NEW DEVELOPMENTS
Chapter- 12: MARKET BY DRUG TYPE
MARKET SIZE
MARKET SHARE
VACCINES
ANTIVIRALS
INTERFERONS
IMMUNE GLOBULINS
CHEMOTHERAPY
TARGETED THERAPY
CHELATING AGENTS
CORTICOSTEROIDS
IMMUNOSUPPRESSIVE AGENTS
ANTIMETABOLITES
ANABOLIC STEROIDS
ALCOHOL ABUSE DRUGS
Anti-rejection Medication
INFECTION-FIGHTING DRUGS
ANTIFUNGAL PROPHYLAXIS
GALLSTONE SOLUBILIZING AGENTS
OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES
Chapter- 13: PATENT ANALYSIS
PATENTS BY YEAR
PATENTS BY TYPE
PATENTS BY COUNTRY
PATENTS BY COMPANY
PATENTS BY ASSIGNEE
Table 85 : NUMBER OF PATENTS BY ASIGNEE, 2005–2009
Figure 52 : NUMBER OF PATENTS BY ASSIGNEE, 2005–2009
Chapter- 14: COMPANY PROFILES
ABBOTT LABORATORIES
ACTAVIS U.S.
ALKERMES, INC
ALNYLAM PHARMACEUTICALS
BARR PHARMACEUTICALS
BAYER SCHERING PHARMA AG
BIOTEST PHARMACEUTICALS CORPORATION
BRISTOL-MYERS SQUIBB
CANGENE CORPORATION
DEBIOPHARM GROUP
ELI LILLY & COMPANY

5. FOREST LABORATORIES, INC.
GALMED MEDICAL RESEARCH, LTD.
GILEAD SCIENCES, INC.
GLAXOSMITHKLINE PLC
HUMAN GENOME SCIENCES
IDENIX PHARMACEUTICALS INC.
KINEMED, INC.
MALLINCKRODT
MEDA PHARMACEUTICALS
MERCK & CO.
NOVARTIS AG
PAR PHARMACEUTICAL COMPANIES, INC.
ROCHE
ROXANE LABORATORIES, INC.
SANOFI AVENTIS
SAVIENT PHARMACEUTICALS, INC.
SCHERING-PLOUGH
SCYNEXIS
TALECRIS BIOTHERAPEUTICS
TEVA PHARMACEUTICAL INDUSTRIES LTD.
THREE RIVERS PHARMACEUTICALS
UPSHER-SMITH LABORATORIES
VALEANT PHARMACEUTICALS INTERNATIONAL
VERTEX PHARMACEUTICALS INCORPORATED
WATSON PHARMACEUTICALS, INC.
WYETH INC.
ZYDUS PHARMACEUTICALS INC.
ZYMOGENETICS
Chapter- 15: APPENDIX
Abbreviations
List of Tables
Summary Table : GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014
Table 1 : TYPES OF LIVER DISEASES
Table 2 : APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005–2008
Table 3 : NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES,
2005–2008
Table 4 : NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005–
2008
Table 5 : RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005–2008
Table 6 : HEPATITIS BURDEN IN THE UNITED STATES (2005–2006)
Table 7 : INCIDENCE OF ACUTE HEPATITIS BY SEX AND AGE IN THE UNITED STATES
(2006)
Table 8 : VACCINES FOR HEPATITIS A PREVENTION
Table 9 : VACCINES FOR HEPATITIS B PREVENTION
Table 10 : NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
Table 11 : NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
Table 12 : PROTEASE INHIBITORS USED TO TREAT HEPATITIS

6. Table 13 : INTERFERONS USED TO TREAT HEPATITIS
Table 14 : IMMUNE GLOBULINS USED TO TREAT HEPATITIS
Table 15 : CHEMOTHERAPUTIC DRUGS USED TO TREAT LIVER CANCER
Table 16 : TARGETED THERAPY USED TO TREAT LIVER CANCER
Table 17 : DRUGS USED TO TREAT WILSON’S DISEASE
Table 18 : CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
Table 19 : IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
Table 20 : ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
Table 21 : ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE
Table 22 : ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE
Table 23 : ANTI-REJECTION MEDICATIONS
Table 24 : ANTI-INFECTIVES
Table 25 : ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
Table 26 : GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTY
LIVER DISEASE
Table 27 : OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
Table 28 : HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008
Table 29 : NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY
MANUFACTURER, 2008
Table 30 : NUCLEOTIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY
MANUFACTURER: 2008
Table 31 : INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008
Table 32 : IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER,
2008
Table 33 : CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER,
2008
Table 34 : TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY
MANUFACTURER, 2008
Table 35 : CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE
BY MANUFACTURER, 2008
Table 36 : CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE
BY MANUFACTURER, 2008
Table 37 : IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE:
MARKET SHARE BY MANUFACTURER, 2008
Table 38 : ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY
MANUFACTURER, 2008
Table 39 : ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET
SHARE BY MANUFACTURER, 2008
Table 40 : ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008
Table 41 : ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET
SHARE BY MANUFACTURER, 2008
Table 42 : ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY
MANUFACTURER, 2008
Table 43 : ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET
SHARE BY MANUFACTURER, 2008
Table 44 : GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008
Table 45 : OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE:
MARKET SHARE BY MANUFACTURER, 2008
Table 46 : GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE,

7. THROUGH 2014
Table 47 : GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014
Table 48 : GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014
Table 49 : GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014
Table 50 : GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES,
THROUGH 2014
Table 51 : GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, THROUGH
2014
Table 52 : GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES,
THROUGH 2014
Table 53 : DRUGS THAT CAN CAUSE LIVER DISEASE
Table 54 : NUMBER OF CLINICAL TRIALS FOR HEPATITIS/ LIVER-INDUCED LIVER DISEASES
Table 55 : NUMBER OF CLINICAL TRIALS FOR LIVER TUMORS
Table 56 : NUMBER OF CLINICAL TRIALS FOR CONGENITAL LIVER DEFECTS
Table 57 : NUMBER OF CLINICAL TRIALS FOR AUTOIMMUNE LIVER DISORDERS
Table 58 : NUMBER OF CLINICAL TRIALS FOR ALCOHOL-INDUCED LIVER DISEASES
Table 59 : NUMBER OF CLINICAL TRIALS FOR CHRONIC LIVER DISEASES
Table 60 : NUMBER OF CLINICAL TRIALS FOR NON-ALCOHOLIC FATTY LIVER DISEASE
Table 61 : GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, THROUGH 2014
Table 62 : SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008
Table 63 : GLOBAL SALES OF HEPATITIS VACCINE, THROUGH 2014
Table 64 : GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY
REGION, THROUGH 2014
Table 65 : GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY
REGION, THROUGH 2014
Table 66 : GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION,
THROUGH 2014
Table 67 : GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION,
THROUGH 2014
Table 68 : GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY
REGION, THROUGH 2014
Table 69 : GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION,
THROUGH 2014
Table 70 : GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION,
THROUGH 2014
Table 71 : GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION,
THROUGH 2014
Table 72 : GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES,
BY REGION, THROUGH 2014
Table 73 : GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION,
THROUGH 2014
Table 74 : GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY
REGION, THROUGH 2014
Table 75 : GLOBAL SALES OF ALCOHOL ABUSE DRUGS BY REGION, 2007-2014
Table 76 : GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES,
BY REGION, THROUGH 2014
Table 77 : GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT
PATIENTS, BY REGION, THROUGH 2014
Table 78 : GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY

8. REGION, THROUGH 2014
Table 79 : GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, THROUGH
2014
Table 80 : GLOBAL SALES OF OTHER DRUGS USED TO TREAT NON- ALCOHOLIC FATTY
LIVER DISEASES, BY REGION, THROUGH 2014
Table 81 : TOTAL NUMBER OF PATENTS EACH YEAR, 2005–2009
Table 82 : NUMBER OF PATENTS BY TYPE, 2005–2009
Table 83 : TOTAL NUMBER OF PATENTS BY COUNTRY, 2005–2009
Table 84 : NUMBER OF PATENTS BY COMPANY, 2005–2009
Table 85 : NUMBER OF PATENTS BY ASIGNEE, 2005–2009
List of Figures
Summary Figure : GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014
Figure 1 : NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES,
2005–2008
Figure 2 : HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008
Figure 3 : NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY
MANUFACTURER, 2008
Figure 4 : NUCLEOTIDE ANALOGS TO TREAT HEPATITS: MARKET SHARE BY
MANUFACTURER, 2008
Figure 5 : INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008
Figure 6 : IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER,
2008
Figure 7 : CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER,
2008
Figure 8 : TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY
MANUFACTURER, 2008
Figure 9 : CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE
BY MANUFACTURER, 2008
Figure 10 : CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE
BY MANUFACTURER, 2008
Figure 11 : IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE:
MARKET SHARE BY MANUFACTURER, 2008
Figure 12 : ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE
BY MANUFACTURER, 2008
Figure 13 : ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET
SHARE BY MANUFACTURER, 2008
Figure 14 : ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008
Figure 15 : ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET
SHARE BY MANUFACTURER, 2008
Figure 16 : ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY
MANUFACTURER, 2008
Figure 17 : ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET
SHARE BY MANUFACTURER, 2008
Figure 18 : GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008
Figure 19 : OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE:
MARKET SHARE BY MANUFACTURER, 2008
Figure 20 : GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE,
2007-2014

9. Figure 21 : GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014
Figure 22 : GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014
Figure 23 : GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014
Figure 24 : GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES,
2007-2014
Figure 25 : GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, 2007-2014
Figure 26 : GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES,
2007-2094
Figure 27 : GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, 2007-2014
Figure 28 : SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008
Figure 29 : GLOBAL SALES OF HEPATITIS VACCINE, 2007-2014
Figure 30 : GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY
REGION, 2007-2014
Figure 31 : GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY
REGION, 2007-2014
Figure 32 : GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION,
2007-2014
Figure 33 : GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY
REGION, 2007-2014
Figure 34 : GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY
REGION, 2007-2014
Figure 35 : GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION,
2007-2014
Figure 36 : GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY
REGION, 2007-2014
Figure 37 : GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION,
2007-2014
Figure 38 : GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES,
BY REGION, 2007-2014
Figure 39 : GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION,
2007-2014
Figure 40 : GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY
REGION, 2007-2014
Figure 41 : GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, 2007-2014
Figure 42 : GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES,
BY REGION, 2007-2014
Figure 43 : GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT
PATIENTS, BY REGION, 2007-2014
Figure 44 : GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY
REGION, 2007-2014
Figure 45 : GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, 2007-2014
Figure 46 : GLOBAL SALES OF OTHER DRUGS USED IN THE TREATMENT OF NON-
ALCOHOLIC FATTY LIVER DISEASES, BY REGION, 2007-2014
Figure 47 : TOTAL NUMBER OF PATENTS EACH YEAR, 2005–2009
Figure 48 : NUMBER OF PATENTS BY TYPE, 2005–2009
Figure 49 : PATENTS, SHARE BY TYPE, 2005–2009
Figure 50 : TOTAL NUMBER OF PATENTS BY COUNTRY, 2005–2009
Figure 51 : TOTAL NUMBER OF PATENTS BY COMPANY, 2005–2009
Figure 52 : NUMBER OF PATENTS BY ASSIGNEE, 2005–2009

10. Latest Market Research Reports:
 Merchant Hydrogen Generation and On-site Distributed Generation
 Global Markets for Flame Retardant Chemicals and Plastics
 The Global Catheters Market
 DNA Sequencing: Emerging Technologies and Applications
 2011 Fuel Cell Industry Review
 2011 Hybrid & Electric Vehicle Progree Review
About Us:
ReportsnReports is an online library of over 75,000 market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit Our Market Research Reports Blog